Asuragen, Focus in diagnostics partnership
This article was originally published in Clinica
Molecular diagnostics specialist Asuragen has granted non-exclusive worldwide rights for its armoured RNA technology to Focus Diagnostics. The deal will see Focus, the Cypress, California-based infectious disease diagnostics subsidiary of Quest Diagnostics, incorporate Asuragen’s technology into its in vitro molecular diagnostics products. Financial terms of the deal were not revealed. According to Asuragen (Austin, Texas), its armoured RNA technology is designed to package RNA or DNA in baceteriophage coat proteins for protection and stabilisation.
You may also be interested in...
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals